TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17913754
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no sevoflurane administration)
Study: 18451319
Drug: Tidal volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tidal volume of 12 ml/kg
Study: 11866252
Drug: Standard naltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard naltrexone treatment
Study: 10361962
Drug: Moclobemide 450
Normalized name: moclobemide
DrugBank: Moclobemide (DB01171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide 450 mg per day
Study: 10361962
Drug: Clomipramine 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine 150 mg per day
Study: 1723407
Drug: Current chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current chemotherapy for advanced testicular cancer
Study: 7258824
Drug: 0.5% FPL‐55712
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% FPL‐55712 (SRS‐A antagonist)
Study: 7258824
Drug: 1% FPL‐55712
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% FPL‐55712 (SRS‐A antagonist)
Study: 20522167
Drug: SQ and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ and IV insulin therapy
Study: 19270234
Drug: Daily hemodialysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily hemodialysis (dHD)
Study: 17365745
Drug: d,l-fenfluramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: d,l-fenfluramine
Study: 15128636
Drug: Propofol 4
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 4 to 10 mg x kg(‐1) x hr(‐1) with 60% nitrous oxide in oxygen
Study: 7872995
Drug: Nebulized salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized salbutamol sulfate (Asmasal) at 0.1 mg/kg
Study: 7872995
Drug: Nebulized salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized salbutamol sulfate (Asmasal) at 0.2 mg/kg
Study: 7872995
Drug: Nebulized salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized salbutamol sulfate (Asmasal) at 0.3 mg/kg
Study: 3243221
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of classroom and home-based curriculum
Study: 29192349
Drug: Placement of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placement of an antibiotic oral pack on the hard palate for 5 days postoperatively (Group A)
Study: 29192349
Drug: No oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No oral pack placed (Group B)
Study: 22452894
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy plus celecoxib (arm D)
Study: 22452894
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy alone (control arm A)
Study: 17609682
Drug: Dose adjustment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose adjustment
Study: 15806597
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of EX/RP and CMI (EX/RP+CMI)
Study: 7879933
Drug: Atracurium (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium (0.5 mg.kg-1)
Study: 7879933
Drug: Vecuronium (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium (0.1 mg.kg-1)
Study: 2196355
Drug: Dexamethasone, 2
Normalized name: Dexamethasone, 2 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone, 2 mg/kg/day by intravenous injection during the first 7 days of life (group A1)
Study: 2196355
Drug: 10% dextrose
Normalized name: Aminosyn II 4.25% in 10% Dextrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% dextrose solution placebo (group A2)
Study: 30659815
Drug: Short-term ontopsychological
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term ontopsychological psychotherapy plus routine medical therapy
Study: 30659815
Drug: Routine medical
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine medical therapy only
Study: 20147571
Drug: MRK-409 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRK-409 at a dose of 2 mg
Study: 20147571
Drug: MRK-409 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRK-409 at a dose of 1 mg
Study: 19672771
Drug: CDA 0.14
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDA 0.14 mg/kg/day for 5 days (Arm A)
Study: 19672771
Drug: CDA 0.14
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDA 0.14 mg/kg/day once weekly for 5 weeks (Arm B)
Study: 15100717
Drug: 3.5 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5 g/day fish oil (1.5 g/day n-3 fatty acids)
Study: 11167438
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg at induction and ondansetron 0.13 mg with each 1-mg bolus dose of morphine
Study: 11167438
Drug: Droperidol 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 0.5 mg at induction and droperidol 0.05 mg per 1-mg bolus dose of morphine
Study: 9924238
Drug: itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: itraconazole 200 mg orally, once daily for 4 days
Study: 7508827
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium chloride (0.3 mEq/kg bolus over 10 minutes followed by 0.08 mEq/kg per hour for 24 hours)
Study: 7508827
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium chloride
Study: 2906956
Drug: labetalol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: labetalol (1 mg/kg i.v. 15 min)
Study: 24726210
Drug: losartan 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: losartan 150 mg/d
Study: 24726210
Drug: losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: losartan 50 mg/d
Study: 23275363
Drug: Exenatide once
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide once weekly (EQW) 2 mg
Study: 23275363
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir (once or twice daily, titrated)
Study: 10974044
Drug: DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA supplementation (200 mg of DHA/day)
Study: 8733069
Drug: Carvedilol 50
Normalized name: carvedilol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 50 mg bid
Study: 16598518
Drug: Carvedilol 25
Normalized name: carvedilol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 25 mg bid
Study: 8733069
Drug: Intravenous carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous carvedilol followed by oral carvedilol 50 mg bid for 8 weeks
Study: 1303781
Drug: Immunologically active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunologically active peat preparation (PTT)
Study: 26946967
Drug: Probiotic S.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic S. boulardii (50 mg/kg twice daily)
Study: 19822590
Drug: Guided imagery
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided imagery treatment
Study: 19822590
Drug: Guided imagery
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided imagery treatment after standard medical care
Study: 19822590
Drug: Guided imagery
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided imagery treatment effects maintained for 6 months
Study: 15190043
Drug: High-flavonoid dark
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flavonoid dark chocolate (213 mg procyanidins, 46 mg epicatechin)
Study: 15190043
Drug: Low-flavonoid dark
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-flavonoid dark chocolate (46 g, 1.6 oz)
Study: 11735841
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care plus a 15-session group cognitive therapy prevention program
Study: 8192116
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of ondansetron (0.15 mg/kg) with dexamethasone (20 mg)
Study: 8192116
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of ondansetron (0.15 mg/kg) with dexamethasone (20 mg)
Study: 25231632
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive (COC) users
Study: 31983034
Drug: Very low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low dose COCs (20 mcg EE)
Study: 27926561
Drug: Glyceryl trinitrate
Normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glyceryl trinitrate ointment (twice daily for 8 weeks)
Study: 23525894
Drug: MK-7 (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-7 (180 μg MK-7/day)
Study: 19682342
Drug: IV ferric
Normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV ferric carboxymaltose (≤1000 mg over 15 min, repeated weekly)
Study: 18928998
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulfate (325 mg orally thrice daily for 6 weeks)
Study: 16769917
Drug: Life-prolonging therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Life-prolonging therapy from the ICD
Study: 12572702
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy following surgery
Study: 11795434
Drug: Finasteride (5-alpha-reductase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride (5-alpha-reductase inhibitor)
Study: 9397979
Drug: Lactulose (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose (45 mL/d) for 8 weeks
Study: 31268011
Drug: Infusion therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion therapy
Study: 27058907
Drug: Medication Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication Therapy Management review and CVD risk assessment and education
Study: 25504176
Drug: Dyadic music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dyadic music therapy intervention (10 weekly sessions)
Study: 22824755
Drug: Fermented papaya
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermented papaya preparation (FPP) 9g/day (4.5g twice a day sublingually) for 6 weeks
Study: 28810801
Drug: Fermented papaya
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermented papaya preparation (FPP)
Study: 20846428
Drug: Weekly CCQ
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly CCQ assessment
Study: 15956086
Drug: naloxone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: naloxone (8 mg) preceding beta-endorphin infusion
Study: 2692962
Drug: HRP112 (depot‐medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRP112 (depot‐medroxyprogesterone acetate, 25 mg and estradiol cypionate, 5 mg)
Study: 48894
Drug: Procainamide (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procainamide (500 mg, 4-hourly)
Study: 48894
Drug: Mexiletine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexiletine (250 mg, 8-hourly)
Study: 29148088
Drug: Intensive intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive intervention (four weekly group sessions and two motivational follow-up calls)
Study: 22856637
Drug: 0.5 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/day of jet‐nebulized budesonide inhalation suspension (BIS)
Study: 22856637
Drug: 40-60 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40-60 mg/day of cromolyn sodium inhalation suspension (CIS)
Study: 15934131
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy and telephone contact
Study: 9183510
Drug: Group-based relapse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based relapse prevention (G-RP)
Study: 9183510
Drug: Relapse prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relapse prevention treatment (both formats)
Study: 29405780
Drug: High-protein diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein diet (HP: 2.5 g·kg‐1·day‐1; n=8)
Study: 29405780
Drug: Low-protein diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein diet (LP: 0.9 g·kg‐1·day‐1; n=9)
Study: 24112515
Drug: Nevirapine XR
Normalized name: nevirapine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nevirapine XR formulation
Study: 20467878
Drug: Epidural bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural bupivacaine with 4 mg dexamethasone (group BD)
Study: 9646062
Drug: Amorphous erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amorphous erythromycin ethylsuccinate (500 mg)
Study: 9646062
Drug: Crystalline erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Crystalline erythromycin ethylsuccinate (1000 mg)
Study: 7884020
Drug: Cocaine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (20 mg and 40 mg)
Study: 7884020
Drug: Fluoxetine and
Normalized name: fluoxetine and psycholeptics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine and cocaine
Study: 3220956
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg meclizine
Study: 73796
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of 16 g guar and 10 g pectin to the control meal
Study: 73796
Drug: Control meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control meal containing 106 g carbohydrate
Study: 19627897
Drug: Concurrent use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent use of ankle support with wedged insole
Study: 17119140
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment individualized to the patient
Study: 17119140
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (surgery and nonoperative)
Study: 15149345
Drug: High baseline
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High baseline albuminuria (> or =3.0 g/g creatinine)
Study: 16412866
Drug: Aspirin 30,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 30, 100, or 325 mg/day
Study: 11484571
Drug: Aluminous oxide
Normalized name: aluminium oxide
DrugBank: Aluminum oxide (DB11342)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminous oxide pink stone surface treatment
Study: 11484571
Drug: 50‐micron aluminum
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50‐micron aluminum oxide sandblasting surface treatment
Study: 11484571
Drug: Brown rubber
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brown rubber point surface treatment
Study: 11484571
Drug: Gray silicone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gray silicone wheel followed by pink silicone wheel surface treatment
Study: 2849376
Drug: Intranasally administered
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasally administered rhinovirus receptor murine monoclonal antibody (RRMA) 135 micrograms/subject in 9 applications, -17 to +48 h
Study: 2849376
Drug: Intranasally administered
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasally administered rhinovirus receptor murine monoclonal antibody (RRMA) 1 mg/subject in 10 applications, -3 to +36 h
Study: 15004731
Drug: Carvedilol 25
Normalized name: carvedilol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol 25 mg b.i.d. for 6 days
Study: 15004731
Drug: Metoprolol 100
Normalized name: metoprolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 100 mg b.i.d. for 6 days
Study: 1546725
Drug: Mealtime antacids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mealtime antacids (80 mmol/day)
Study: 1546725
Drug: Sucralfate 1
Normalized name: sucralfate 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate 1 g twice a day
Study: 1546725
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg, antacids, ranitidine 150 mg, and sucralfate
Study: 9691103
Drug: Mesalamine 2
Normalized name: mesalamine 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalamine 2 g twice daily
Study: 24929350
Drug: Pegnivacogin 1
Normalized name: Pegnivacogin
DrugBank: Pegnivacogin (DB06293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegnivacogin 1 mg/kg with 25% anivamersen reversal
Study: 24929350
Drug: Pegnivacogin 1
Normalized name: Pegnivacogin
DrugBank: Pegnivacogin (DB06293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegnivacogin 1 mg/kg with 50% anivamersen reversal
Study: 24929350
Drug: Pegnivacogin 1
Normalized name: Pegnivacogin
DrugBank: Pegnivacogin (DB06293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegnivacogin 1 mg/kg with 75% anivamersen reversal
Study: 24929350
Drug: Pegnivacogin 1
Normalized name: Pegnivacogin
DrugBank: Pegnivacogin (DB06293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegnivacogin 1 mg/kg with 100% anivamersen reversal
Study: 20559104
Drug: Tiopronin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiopronin (3 g/d)
Study: 20559104
Drug: Tiopronin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiopronin (1 g/d to 3 g/d)
Study: 15673873
Drug: Stimulation patterns
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulation patterns (300‐500 V; 100‐1000 Hz; 1‐5 stimuli) at different propofol target plasma concentrations (PTPCs) (2, 4, and 6 microg/mL)
Study: 15673873
Drug: Propofol target
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol target plasma concentrations (PTPCs) (2, 4, and 6 microg/mL)
Study: 2268862
Drug: Ketoprofen 75
Normalized name: ketoprofen 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen 75 mg
Study: 30961672
Drug: 4 active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 active ABCR sessions twice a week
Study: 30961672
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group sessions twice a week
Study: 25694300
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro protamine
Study: 23404154
Drug: Left capnothorax
Approvals — FDA: no, EMA: no, PMDA: no
Description: Left capnothorax first (Group L)
Study: 18847131
Drug: Pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatment with antidepressants (specifics not provided)
Study: 12929879
Drug: Calcium intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium intake in children with rickets (285 +/- 113 mg/day)
Study: 12929879
Drug: Calcium intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium intake in adolescents with rickets (305 +/- 196 mg/day)
Study: 12929879
Drug: 25 hydroxyvitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 hydroxyvitamin D in children with rickets (49 +/- 38 nmol/l)
Study: 12929879
Drug: Serum 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum 25 hydroxyvitamin D in adolescents with rickets (12.6 +/- 7.1 nmol/l)
Study: 12929879
Drug: Odds ratio
Approvals — FDA: no, EMA: no, PMDA: no
Description: Odds ratio for developing rickets with daily calcium intake below 300 mg
Study: 12929879
Drug: Calcium treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium treatment (1 g daily) in children
Study: 12929879
Drug: Calcium treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium treatment (1 g daily) in adolescents
Study: 1357124
Drug: sCD4 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: sCD4 plus dideoxyinosine (90 mg/m2 every 8 hours)
Study: 1357124
Drug: sCD4 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: sCD4 plus dideoxyinosine combination therapy
Study: 2409543
Drug: Flecainide acetate
Normalized name: Flecainide Acetate
DrugBank: Flecainide (DB01195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flecainide acetate (200 mg twice daily)
Study: 27852545
Drug: Synbiotic preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synbiotic preparation containing Lactobacillus casei, L. plantarum, L. rhamnosus, Bifidobacterium lactis and prebiotics
Study: 27852545
Drug: Zinc suspension
Normalized name: Human insulin zinc suspension crystalline
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc suspension (15 mg/day for 5 days)
Study: 27852545
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (ORS and/or intravenous therapy)
Study: 23242727
Drug: Hydrocortisone +
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone + mupirocin ointment
Study: 23242727
Drug: Emollient ointment
Normalized name: diflorasone
DrugBank: Diflorasone (DB00223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emollient ointment